Clinical Trial Update: A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating HEC585 to delay decline in forced vital capacity in progressive fibrosing interstitial lung disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Fibrosing Interstitial Lung Disease
• Progressive Pulmonary Fibrosis

Drugs mentioned

• HEC585

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | Phase 2 | Status: RECRUITING